STORM Therapeutics raises $56M Series C and doses first patient in Phase 2 sarcoma trial of STC-15, the world’s first RNA enzyme drug to reach human trials.

TNW is a technology media company that covers the latest trends, news, and insights in the tech industry. With a focus on innovation, entrepreneurship, and digital culture, TNW offers resources for developers, startups, and tech enthusiasts. Developers can learn about emerging technologies, industry trends, and best practices through TNW's articles, podcasts, and events.

The Next Web

STORM Therapeutics, a Cambridge biotech, has raised $56M in a Series C round backed entirely by existing investors including Pfizer Ventures and M Ventures. The company has also dosed the first patient in a Phase 2 trial of STC-15, the world's first RNA-modifying enzyme inhibitor to reach human clinical trials. STC-15 targets METTL3, an enzyme that methylates mRNA and is exploited by certain cancers to maintain malignant cell proliferation. Phase 1 results showed durable tumour regression across multiple sarcoma subtypes. The Phase 2 trial focuses on selected sarcoma indications and is designed to support an accelerated regulatory approval pathway. STC-15 is also being evaluated in combination with a PD-1 inhibitor across several other cancer types.

Cambridge biotech STORM Therapeutics raises $56M